Abstract
SPAG9 is a further new antigen that might be a candidate for clinical use. In particular the high frequency of mRNA expression in different solid tumours and haematological malignancies is a prerequisite for a potentially wide use. Most of the tested CML patients showed humoral immune responses against SPAG9. Nevertheless, specific CD8-positive T cell-responses and clinical efficacy analogue to the targets RHAMM or WT-1 have to be shown.
Publication types
-
Editorial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adaptor Proteins, Signal Transducing / antagonists & inhibitors
-
Adaptor Proteins, Signal Transducing / immunology*
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use*
-
Antigens, Neoplasm / immunology*
-
CD8-Positive T-Lymphocytes / immunology
-
Cancer Vaccines / immunology*
-
Cancer Vaccines / therapeutic use
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
Drug Delivery Systems
-
Drug Design
-
Female
-
Humans
-
Immunotherapy, Active
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / prevention & control
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
-
Male
-
Vaccination
Substances
-
Adaptor Proteins, Signal Transducing
-
Antibodies, Monoclonal
-
Antigens, Neoplasm
-
Cancer Vaccines
-
SPAG9 protein, human